Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > April 9, 2025
Daily News
April 9, 2025
- KM Biologic President to Be Promoted to Meiji Group’s Pharma Chief
April 9, 2025
- Label Revisions Ordered for Xtandi, Paxlovid, and More Drugs
April 9, 2025
- Revise Regulations of Clinical Trial Info in PMD Act: Patient Advocate to Diet
April 9, 2025
- FPMAJ Renews Call for Scrapping Off-Year Drug Price Revision: Diet Hearing
April 9, 2025
- Japan Economic Minister Akazawa to Lead Tariff Talks with US
April 9, 2025
- Daiichi Sankyo’s Datroway Approved in Europe for Breast Cancer
April 9, 2025
- No. 1 Priority of Public-Private Council Must Be Drug Pricing: PhRMA Japan Chair
April 9, 2025
- JCR to Fuel Licensing of J-Brain Cargo, Invest in Global R&D: President
April 9, 2025
- Japan Infectious Disease Market Projected to Drop to 771.8 Billion Yen in 2033: Fuji Keizai
April 9, 2025
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…